Combination treatment with chemotherapeutic agents in vitro also enhance murine TRAIL-R1 and TRAIL-R2 agonistic antibody-induced cell killing (Ohtsuka et al, 2003), and combination of a murine TRAIL-R2 antibody with adriamycin or paclitaxel showed greater inhibition of tumour growth compared to antibody alone in a breast cancer model in vivo (Buchsbaum et al, 2003). Here, TNFRSF10B is linked to neoplasm.